Silence Therapeutics Plc Stock Price, News & Analysis
Company Description
Silence Therapeutics Plc (OTC Link: SLNCF) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $226.7M.
SLNCF stock has gained 143.3% over the past year. Shares last traded at $2.36.
On a trailing twelve-month basis, Silence Therapeutics Plc reported revenue of $559K with net income of -$88.6M and diluted earnings per share of $-0.63. The company operates at a net profit margin of -15851.9%.
This page provides a comprehensive overview of SLNCF stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Silence Therapeutics Plc (SLNCF) stock last traded at $2.36. Over the past 12 months, the stock has gained 143.3%. At a market capitalization of $226.7M, SLNCF is classified as a micro-cap stock with approximately 141.7M shares outstanding.
SLNCF Rankings
Latest News
Silence Therapeutics Plc has 3 recent news articles. Key topics include management. View all SLNCF news →
SEC Filings
Silence Therapeutics Plc has filed 8 recent SEC filings, including 2 Form 4, 2 Form 10-K, 2 Form 8-K, 2 Form SCHEDULE 13G/A. The most recent filing was submitted on March 5, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SLNCF SEC filings →
Financial Highlights
Silence Therapeutics Plc generated $559K in revenue over the trailing twelve months, retaining a 61.5% gross margin, operating income reached -$91.1M (-16292.8% operating margin), and net income was -$88.6M, reflecting a -15851.9% net profit margin. Diluted earnings per share stood at $-0.63. The company generated -$62.3M in operating cash flow. With a current ratio of 8.72, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Silence Therapeutics Plc (SLNCF) currently stands at 755 shares, representing 0.0% of the float. This relatively low short interest suggests limited bearish sentiment. With 1000.0 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Silence Therapeutics Plc (SLNCF) currently stands at 1000.0 days, up 31645.7% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 58039% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.7 to 1000.0 days.
SLNCF Company Profile & Sector Positioning
Silence Therapeutics Plc (SLNCF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing SLNCF often look at related companies in the same sector, including Bioinvent Intern (BOVNF), Hansa Medical AB (HNSBF), Oryzon Genomics (ORYZF), Nervgen Pharma Corp (NGENF), and Adocia (ADOCY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SLNCF's relative position within its industry.